The FDA has approved the first ever blood-based companion diagnostic test. The cobas EGFR Mutation Test v2 was developed by Roche for the drug erlotinib (Tarceva), which was developed by Astellas for the treatment of non-small cell lung cancer.
The FDA has approved the first ever blood-based companion diagnostic test. The cobas EGFR Mutation Test v2 was developed by Roche for the drug erlotinib (Tarceva), which was developed by Astellas for the treatment of non-small cell lung cancer (NSCLC).
Tumor cells in patients with NSCLC are released into the circulation, which can then be isolated from the patient’s blood sample for detecting specific mutations—a process called “liquid biopsy.” According to Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health, “Liquid biopsies also have the potential to allow physicians to identify patients whose tumors have specific mutations in the least invasive way possible.”
Between 10% and 20% of NSCLC patients are known to harbor the exon 19 deletion or exon 21 (L858R) substitution mutations that the test can identify. Roche evaluated this molecular diagnostic test using blood samples from NSCLC patients whose tumor biopsies were positive for EGFR exon 19 deletion or L858R mutations.
While there has been a long-standing debate about the value of liquid biopsy tests in the detection of circulating tumor cells, the cobas EGFR Mutation Test v2 could prove extremely useful in identifying the subset of potential positive responders to erlotinib, in a non-invasive manner. This addresses the fundamental issue of personalizing treatment to avoid unnecessary exposure of those patients who do not harbor the mutation, and also avoids the discomfort associated with retrieving a tumor biopsy sample. Additionally, the turnaround time with a blood-based test could help oncologists make quicker decisions on the treatment path to follow.
A much awaited liquid biopsy test is a pan-cancer diagnostic test being developed by a spin-off of Illumina. “Grail” is being developed for the early detection of cancer in asymptomatic individuals, using a technique called “ultra-deep” sequencing. The project, which had raised more than a $100 million at the beginning of the year, has the backing of a venture capital firm, Arch Venture Partners, Microsoft cofounder Bill Gates, and Amazon’s Jeffrey Bezos.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More